Biotechnology company (ASX-listed)
Appears in 1 story
Co-developer and commercial partner for lixudebart
CSL will pay Swiss biotech Alentis Therapeutics $355 million upfront to co-develop lixudebart, an experimental antibody for rare kidney and liver diseases. Milestones could add $1.2 billion, with profits split 55% to CSL and 45% to Alentis.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
